Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Clinical Trial
Official title:
A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer
| Verified date | July 2022 |
| Source | Roswell Park Cancer Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer. Photodynamic therapy (PDT) uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Giving photodynamic therapy after surgery may kill any tumor cells that remain after surgery.
| Status | Completed |
| Enrollment | 15 |
| Est. completion date | August 30, 2018 |
| Est. primary completion date | October 28, 2011 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients with resectable primary or recurrent head and neck squamous cell carcinomas (HNSCC) who are undergoing surgery to resect the cancer; (operable patients whose disease can be removed surgically with the expectation of clear margins, without compromising vital structures, i.e. respectability is individually determined by the surgeon and is based on anatomic extent of disease as well as technical ability of the operator) - Female patients must not be pregnant (documented by human chorionic gonadotropin [HCG] test) and must be practicing a medically acceptable form of birth control, be sterile or post-menopausal - Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Patients must sign an informed consent according to Food and Drug Administration (FDA) guidelines acceptable to the Roswell Park Cancer Institute (RPCI) Institutional Review Board (IRB) - No radiation therapy, chemotherapy or other biological therapy for at least 30 days prior to PDT Exclusion Criteria: - Patients with unresectable tumors - Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds - White blood cell (WBC) < 4,000 - Platelet count < 100,000 - Prothrombin time 1.5 times above the upper normal limit - Total serum bilirubin > 2.0 mg/d - Serum creatinine > 2 mg% - Alkaline phosphatase (hepatic) > 3 times the upper normal limit - Serum glutamic oxaloacetic transaminase (SGOT) > 3 times the upper normal limit - Patients on concurrent chemotherapy or radiation therapy will be excluded - Patients who have received radiation therapy, chemotherapy or other biological therapy during the past 30 days - Has not recovered from toxicity of prior therapy |
| Country | Name | City | State |
|---|---|---|---|
| United States | Roswell Park Cancer Institute | Buffalo | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Roswell Park Cancer Institute |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Maximum tolerated dose of photodynamic therapy in which 1 of 6 patients experience dose-limiting toxicity | 30 days | ||
| Secondary | Time to tumor progression or recurrence | From baseline until objective tumor progression, assessed up to 5 years | ||
| Secondary | Uptake and distribution of HPPH in resected tumor tissue | Day 2 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01155609 -
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
|
N/A | |
| Completed |
NCT01044433 -
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
|
Phase 2 | |
| Completed |
NCT00407810 -
Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00096512 -
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00098631 -
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00055770 -
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01249443 -
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
|
Phase 1 | |
| Completed |
NCT01637194 -
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT00033618 -
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
|
Phase 2 | |
| Completed |
NCT01816984 -
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01674374 -
Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy
|
Phase 2 | |
| Terminated |
NCT01528137 -
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT01847326 -
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
|
Phase 1 | |
| Completed |
NCT00114283 -
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00055913 -
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01334177 -
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
|
Phase 1 | |
| Completed |
NCT00492089 -
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00939627 -
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
|
Phase 2 | |
| Terminated |
NCT00906360 -
Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
| Completed |
NCT00507767 -
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 |